Reference
Ozempic (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products Drug Safety Update 17: No. 4, 23 Nov 2023. Available from: URL: https://www.gov.uk/drug-safety-update/ozempicv-semaglutide-and-saxenda-liraglutide-vigilance-required-due-to-potentially-harmful-falsified-products
Rights and permissions
About this article
Cite this article
Falsified Ozempic (semaglutide) and Saxenda (liraglutide). Reactions Weekly 1986, 2 (2023). https://doi.org/10.1007/s40278-023-51307-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-51307-9